Journal of Pharmaceutical and Biomedical Sciences

Recently, a new class of in vitro and ex vivo radiotracers/radioprotectors, the nitroxyl–labeled agent N-[N'-(2-chloroethyl)-N’-nitrosocarbamoylglycine amide of 2,2,6,6-tetramethyl-4aminopiperidine-1-oxyl (SLCNUgly), has been discovered. Our previous investigations demonstrated that SLCNUgly is a low-molecular-weight stable free radical which is freely membrane permeable, easily crosses the blood brain barrier and exhibited in/ex vivo the lowest general toxicity and higher anticancer activity against some experimental tumor models. Further investigation was aimed to develop a Tclabeled SLCNUgly (96.5%) as a chelator and evaluate its labeling efficiency and potential use as a tumor seeking agent and for early diagnosis. Tissue biodistribution of TcSLCNUgly was determined in normal mice at 1, 2, and 24 h (n=4/ time interval, route of administration i.v.). The distribution data was compared to that using male albino non-inbred mice Original article